Literature DB >> 20401641

Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC).

Yu Yang1, Jiang Zhu, Hongfeng Gou, Dan Cao, Ming Jiang, Mei Hou.   

Abstract

Cox-2, Survivin and Bcl-2 are frequently overexpressed in numerous types of cancers. They are known to be the important regulators of apoptosis. This study was designed to investigate the correlation between the clinical characteristics and the expression of Cox-2, Survivin and Bcl-2 in hepatocellular carcinoma. A total of 63 postoperative hepatocellular carcinoma (HCC) samples, 10 adjacent non-tumor samples and 10 normal liver samples were immunochemically detected for the expression of Cox-2, Survivin and Bcl-2. A median follow-up of 4 years for the 63 HCC patients was conducted. Univariate tests and multivariate Cox regression were performed for statistical analysis. The Kaplan-Meier method was used to analyze the survival. Positive expression of Cox-2 (84.3%) and Survivin (77.8%) was detected significantly more frequently in the HCC samples than in the normal liver tissues (30% and 0, respectively). Bcl-2 was highly expressed in the adjacent non-tumor tissue. Cox-2 was positively correlative to Survivin. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC (P<0.05). Expression of both Cox-2 and Survivin was significantly associated with the poor overall survival (OS) (P=0.0141, P=0.0039). Furthermore, multivariate analysis confirmed the independent prognostic value of Survivin expression, along with tumor size and hepatic function. Cox-2 and Survivin were highly expressed in the HCC tissue. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC. The expression of Survivin was an independent prognostic factor for HCC after a hepatectomy. Treatment that inhibits Survivin may be a promising targeted approach in HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20401641     DOI: 10.1007/s12032-010-9519-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

Authors:  Robin K Kelley; Alan P Venook
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

3.  A survivin gene signature predicts aggressive tumor behavior.

Authors:  Whitney Salz; Dan Eisenberg; Janet Plescia; David S Garlick; Robert M Weiss; Xue-Ru Wu; Tung-Tien Sun; Dario C Altieri
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

4.  Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level.

Authors:  Fernando Martínez-Arribas; Teresa Alvarez; Gabriela Del Val; Elena Martín-Garabato; María-José Núñez-Villar; Raul Lucas; Jaime Sánchez; Armando Tejerina; José Schneider
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

5.  Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giuseppe Tonini; Susanna Scarpa; Fortunata Vasaturo; Carolina Malacrino; Fabio Vecchio; Domenico Borzomati; Sergio Valeri; Roberto Coppola; Paolo Magistrelli; Gennaro Nuzzo; Aurelio Picciocchi
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 6.  Celecoxib: a specific COX-2 inhibitor with anticancer properties.

Authors:  Alane T Koki; Jaime L Masferrer
Journal:  Cancer Control       Date:  2002 Mar-Apr       Impact factor: 3.302

7.  COX-2-dependent stabilization of survivin in non-small cell lung cancer.

Authors:  Kostyantyn Krysan; Farrukh H Merchant; Li Zhu; Mariam Dohadwala; Jie Luo; Ying Lin; Nathalie Heuze-Vourc'h; Mehis Põld; David Seligson; David Chia; Lee Goodglick; Hejing Wang; Robert Strieter; Sherven Sharma; Steven Dubinett
Journal:  FASEB J       Date:  2003-11-03       Impact factor: 5.191

8.  Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Authors:  Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charles S Fuchs; David P Ryan; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

9.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

10.  Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.

Authors:  N Barnes; P Haywood; P Flint; W F Knox; N J Bundred
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  25 in total

1.  Prostaglandin E2 accelerates invasion by upregulating Snail in hepatocellular carcinoma cells.

Authors:  Min Zhang; Hai Zhang; Shanyu Cheng; Dengcai Zhang; Yan Xu; Xiaoming Bai; Shukai Xia; Li Zhang; Juan Ma; Mingzhan Du; Yipin Wang; Jie Wang; Meng Chen; Jing Leng
Journal:  Tumour Biol       Date:  2014-04-24

2.  Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma.

Authors:  Xiaobo Jia; Yingtang Gao; Daokuan Zhai; Jiao Liu; Yajie Wang; L I Jing; Zhi DU
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

3.  The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.

Authors:  M Zhou; M T Mok; H Sun; A W Chan; Y Huang; A S Cheng; G Xu
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

4.  Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis.

Authors:  Ping Chen; Jiang Zhu; Ding-Yi Liu; Hui-Yan Li; Nie Xu; Mei Hou
Journal:  Med Oncol       Date:  2013-12-15       Impact factor: 3.064

5.  ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles.

Authors:  Wonhyo Seo; Yanhang Gao; Yong He; Jing Sun; Hongqin Xu; Dechun Feng; Seol Hee Park; Young-Eun Cho; Adrien Guillot; Tianyi Ren; Ruihong Wu; Jingyun Wang; Seung-Jin Kim; Seonghwan Hwang; Suthat Liangpunsakul; Yingzi Yang; Junqi Niu; Bin Gao
Journal:  J Hepatol       Date:  2019-07-04       Impact factor: 25.083

6.  Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells.

Authors:  Xiangxuan Zhao; Olorunseun O Ogunwobi; Chen Liu
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.752

7.  Hepatitis C virus activates Bcl-2 and MMP-2 expression through multiple cellular signaling pathways.

Authors:  Youxing Li; Qi Zhang; Yin Liu; Zhen Luo; Lei Kang; Jing Qu; Weiyong Liu; Xueshan Xia; Yingle Liu; Kailang Wu; Jianguo Wu
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

8.  Interplay between cyclooxygenase‑2 and microRNAs in cancer (Review).

Authors:  Zexiong Gong; Weiguo Huang; Baiyun Wang; Na Liang; Songkai Long; Wanjun Li; Qier Zhou
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

9.  Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis.

Authors:  Chunguang Li; Zhigang Li; Maoling Zhu; Tiejun Zhao; Ling Chen; Weidan Ji; Hezhong Chen; Changqing Su
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

10.  Survivin regulates the expression of VEGF-C in lymphatic metastasis of breast cancer.

Authors:  Xiaopeng Cai; Shuai Ma; Ming Gu; Cong Zu; Wenzhi Qu; Xinyu Zheng
Journal:  Diagn Pathol       Date:  2012-05-18       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.